EICHORCondition: Coronavirus Infection · COVID-19 · Sponsor: Vanda Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Ability and acceptance to provide written informed consent and fluent in English. * Men or women between 18-100+ years, inclusive. * Willing to comply with study procedures. * SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Vanda Investigational Site | Cleveland, Ohio, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04353401